Cleveland Clinic

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Sunday, November 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
CNS, Sale, Webcast, TMS, POC, Senior, University, Pain, Plasma, Rheumatology, Cleveland Clinic, Patient, Transcranial magnetic stimulation, Psychiatry, Trevena, ARTEMIS, NIH, Epilepsy, Abstract, EEG, S1P, ASA, Central nervous system, Chronic pain, Alertness, Neuropathic pain, Pharmaceutical industry, Medicine, Anesthesiology

ET

Key Points: 
  • ET
    CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2023 and provided an overview of its recent operational highlights.
  • “There is a significant need for safe and effective non-opioid therapies in pain, and for novel mechanisms for the treatment of epilepsy.
  • The Company previously announced preliminary topline data from two Phase 1 proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement.
  • As part of the R-Bridge Financing, Trevena may receive an additional $10 million upon achievement of either a commercial or financing milestone.

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Arm, Safety, Progression-free survival, ODD, TTP, Disease, GBM, Patient, Cleveland Clinic, PFS, Pakistan Society of Neuro-Oncology, FDA, Immunotherapy, Glioblastoma, ORR, University, MD, Cancer, Tips, Society, SNO, Autotransplantation, DRI, Pharmaceutical industry

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting, taking place November 15-19, 2023, in Vancouver, British Columbia. The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM). The first poster is a TIPs poster detailing the study design for INB-400, the company-sponsored Phase 2 trial and the second will be a “late-breaker” poster providing updated clinical data from the Phase 1 INB-200 trial.

Key Points: 
  • The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM).
  • “We are encouraged by the safety and preliminary efficacy signal we have seen in our Phase 1 trial treating GBM patients with autologous, genetically modified gamma-delta T cells.
  • The University of Louisville and The Cleveland Clinic are the first clinical sites activated to enroll patients.
  • GBM remains a disease with significant unmet need, with limited treatment options and poor associated outcomes.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Deltex Medical Group, Annual general meeting, Pakistan Society of Neuro-Oncology, Progression-free survival, University, HSCT, ASH, Cohort, Glioblastoma, TTP, IND, GBM, Leukemia, Patient, Research and development, Abstract, Cleveland Clinic, PFS, Research, Immunotherapy, CRS, IPSC, ORR, CD33, Ovarian cancer, Cancer, Development, CML, Survival, Bone marrow, SITC, Arms, AML, Gamma delta T cell, Society, SNO, CD123, Poster, KOL, University of Chicago, DRI, Pharmaceutical industry, Medical imaging

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

Internationally Recognized Urologist, Robotic Surgeon and Researcher Dr. Andrew J. Stephenson Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Monday, December 18, 2023
Science, Practice Management, Research, Surgery, General Health, Health, Robotics, Technology, Prostate, Corporation, FRCS, National Cancer Institute, PSA, Urology, Clinical research, National Cancer Institute (Egypt), Patient, Cleveland Clinic, Kidney, FACS, Testicle, MBA, MD, NMS, BPH, A.M.P, Hospital, Cancer, Nursing, Syracuse, Central New York

is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .

Key Points: 
  • is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .
  • Dr. Stephenson has performed more than 2,000 robotic urology surgeries in his career.
  • Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.
  • Christopher M. Pieczonka, MD, Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners , stated, “A.M.P.

Ilant Health Wins for Innovative Approach to Obesity Management

Retrieved on: 
Thursday, December 14, 2023
General Health, Professional Services, Health, Human Resources, Health equity, Medicaid, Organization, Cleveland Clinic, Obesity, McKinsey & Company, Home, Population health, IMM, Molina Healthcare, HPIR, Nursing, Anthem, Medicare

Ilant Health, which provides a value-based approach to obesity treatment, is the first company to win all 3 Innovation Roundtable Academies – Employer (EHIR), Health Plan (HPIR), and Provider (PHIR).

Key Points: 
  • Ilant Health, which provides a value-based approach to obesity treatment, is the first company to win all 3 Innovation Roundtable Academies – Employer (EHIR), Health Plan (HPIR), and Provider (PHIR).
  • These groups represent over 100 innovative companies, 14 innovative health plans, and 11 leading provider systems and judging was conducted by individuals from innovative member companies such as State Farm, Premera, and Cleveland Clinic.
  • Companies are assessed for fit with market needs, innovative approach, operational fundamentals, and potential industry impact.
  • This allows Ilant to support different employer types, Medicare, and Medicaid plans, making it one of the few organizations addressing obesity health equity needs.

United States DSUVIA (sufentanil) Drug Insight and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, CNS, Pain, Research, Tablet, Sufentanil, Clinical trial, Cleveland Clinic, Patient, SWOT, Hospital, Cardiopulmonary bypass, Poultry farming, Dietary supplement, Pharmaceutical industry

The "United States DSUVIA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States DSUVIA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about DSUVIA for acute pain in the United States.
  • A detailed picture of the DSUVIA for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the DSUVIA for acute pain.
  • This report provides a detailed market assessment of DSUVIA for acute pain in the United States.

BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds

Retrieved on: 
Wednesday, December 6, 2023
Technology, Medical Devices, Finance, Health Technology, Professional Services, Cardiology, Health, Robotics, General Health, Artery, Tricuspid valve, Investment, Disease, Elective surgery, MMI, Cardiovascular disease, CE marking, Biostar, Instrument, AVS, Cleveland Clinic, Optimism, Pharmaceutical industry

BioStar Capital , a strategic venture capital firm focusing on transformative medical technologies primarily in the fields of cardiovascular disease, orthopedics, and robotics, has announced it has closed its fifth fund at $130.3 million, more than its three previous funds combined.

Key Points: 
  • BioStar Capital , a strategic venture capital firm focusing on transformative medical technologies primarily in the fields of cardiovascular disease, orthopedics, and robotics, has announced it has closed its fifth fund at $130.3 million, more than its three previous funds combined.
  • BioStar expects to invest in 8-10 additional companies over the next five years.
  • In a time of declining investments in venture capital, BioStar’s closing overcame current environmental challenges, demonstrating investor confidence in the firm’s unique model leveraging physician, as well as financial and operational expertise in today’s dynamic healthcare environment.
  • While other venture capital firms are shifting their focus to areas such as cardiovascular medical devices, few have the decades of experience and clinical expertise that BioStar offers through its team of Medical Venture Partners (“MVPs”) and network of physician investors.

Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization

Retrieved on: 
Thursday, November 30, 2023
Medical Devices, Health, AMS, Acquisition, IP, Boston Scientific, Medtronic, Urology, Cleveland Clinic, Male, FDA, Uro, LUTS, Test management, Female, Axon Enterprise, Medical device, Compaq Contura

The Series A funding round includes investment from Laborie and other existing investors in the Company.

Key Points: 
  • The Series A funding round includes investment from Laborie and other existing investors in the Company.
  • Funding will be used to achieve FDA 510(k) clearance of the Glean™ Urodynamics System (Glean) and launch the product in the U.S. in 2024.
  • “Laborie looks forward to leveraging our expertise and leadership in the global urology market to support the Bright Uro team,” said Michael Frazzette, President & CEO of Laborie.
  • Bright Uro Founder and CEO Derek Herrera stated, “I am so proud of our team for achieving this incredible milestone!

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

Retrieved on: 
Wednesday, November 29, 2023
Oncology, Health, Genetics, General Health, Pharmaceutical, Cardiology, Biotechnology, Webcast, Hypertriglyceridemia, GLP, Johnson & Johnson, Janssen Pharmaceuticals, Toxicology, International, RNA interference, Heart, AHA, GSK plc, Cholesterol, PIN, ERS, Patient, Cleveland Clinic, European Respiratory Society, Idiopathic pulmonary fibrosis, American Heart Association, GSK, MD, Janssen, Doctor of Philosophy, ANGPTL3, Triglyceride, Pharmaceutical industry, Medical device, Arrowhead, Medicine, APOC3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.
  • The company is hosting a conference call today, November 29, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018